X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs IPCA LABS - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA IPCA LABS SUN PHARMA/
IPCA LABS
 
P/E (TTM) x 45.1 36.4 123.9% View Chart
P/BV x 3.6 3.5 105.3% View Chart
Dividend Yield % 0.6 0.1 424.6%  

Financials

 SUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
IPCA LABS
Mar-17
SUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs842643 131.0%   
Low Rs572503 113.8%   
Sales per share (Unadj.) Rs131.6254.4 51.7%  
Earnings per share (Unadj.) Rs32.716.1 203.5%  
Cash flow per share (Unadj.) Rs38.029.8 127.5%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %0.50.2 283.5%  
Book value per share (Unadj.) Rs152.7194.6 78.5%  
Shares outstanding (eoy) m2,399.26126.20 1,901.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.42.3 238.6%   
Avg P/E ratio x21.635.7 60.7%  
P/CF ratio (eoy) x18.619.2 96.8%  
Price / Book Value ratio x4.62.9 157.3%  
Dividend payout %10.76.2 172.0%   
Avg Mkt Cap Rs m1,696,87772,300 2,347.0%   
No. of employees `00017.513.3 131.7%   
Total wages/salary Rs m49,0236,960 704.4%   
Avg. sales/employee Rs Th18,028.32,413.5 747.0%   
Avg. wages/employee Rs Th2,798.8523.2 535.0%   
Avg. net profit/employee Rs Th4,479.5152.4 2,938.4%   
INCOME DATA
Net Sales Rs m315,78432,106 983.6%  
Other income Rs m6,232226 2,761.0%   
Total revenues Rs m322,01632,332 996.0%   
Gross profit Rs m100,8934,448 2,268.4%  
Depreciation Rs m12,6481,730 731.3%   
Interest Rs m3,998241 1,660.3%   
Profit before tax Rs m90,4792,703 3,347.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,116675 1,794.4%   
Profit after tax Rs m78,4622,028 3,868.9%  
Gross profit margin %31.913.9 230.6%  
Effective tax rate %13.425.0 53.6%   
Net profit margin %24.86.3 393.4%  
BALANCE SHEET DATA
Current assets Rs m329,53717,340 1,900.5%   
Current liabilities Rs m178,8709,559 1,871.2%   
Net working cap to sales %47.724.2 196.9%  
Current ratio x1.81.8 101.6%  
Inventory Days Days79100 78.7%  
Debtors Days Days8357 146.4%  
Net fixed assets Rs m204,76620,779 985.4%   
Share capital Rs m2,399252 950.6%   
"Free" reserves Rs m363,99724,499 1,485.8%   
Net worth Rs m366,39724,553 1,492.3%   
Long term debt Rs m14,3613,517 408.3%   
Total assets Rs m614,10239,595 1,551.0%  
Interest coverage x23.612.2 193.3%   
Debt to equity ratio x00.1 27.4%  
Sales to assets ratio x0.50.8 63.4%   
Return on assets %13.45.7 234.3%  
Return on equity %21.48.3 259.3%  
Return on capital %24.810.5 236.8%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m44,11815,617 282.5%   
Fx outflow Rs m24,4845,828 420.1%   
Net fx Rs m19,6349,790 200.6%   
CASH FLOW
From Operations Rs m70,8222,764 2,562.1%  
From Investments Rs m-42,216-1,432 2,948.7%  
From Financial Activity Rs m-22,854-1,591 1,436.2%  
Net Cashflow Rs m6,107-259 -2,359.6%  

Share Holding

Indian Promoters % 63.7 45.9 138.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 11.4 45.0%  
FIIs % 23.0 25.3 90.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 17.4 47.7%  
Shareholders   133,026 36,892 360.6%  
Pledged promoter(s) holding % 0.5 2.1 24.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 21, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS